When you think of lung cancer treatment, what comes to mind—chemotherapy, radiation, surgery? While these can be crucial, ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Research shows regular physical activity can significantly improve quality of life for lung cancer patients. This includes ...
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response ...
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune ...
Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and ...